“As an academic clinical investigator and practicing

“As an academic clinical investigator and practicing gastroenterologist, I believe that Brilacidin is an extremely promising mid-phase IBD drug candidate, particularly once formulated for oral delivery,” commented Francis A. Farraye, MD, MSc, Clinical Director, Section of Gastroenterology at Boston Medical Center, Professor of Medicine at Boston University School of Medicine”